Is CROX a Buy After It Soared 47% in July?

NASDAQ: CROX | Crocs, Inc. News, Ratings, and Charts

CROX – Footwear company Crocs, Inc. (CROX) recently won an infringement case, obtaining millions in damages. Moreover, the stock has been on the rise lately. However, given its mixed financials, would it be wise to invest in the stock now? Read on to find out….

Crocs, Inc. (CROX) designs, manufactures and sells casual lifestyle footwear and accessories for men, women, and children. The company offers its various footwear products through wholesalers, retail stores, e-commerce sites, and third-party marketplaces.

In July, CROX announced the judgment of an infringement case against USA Dawgs and Double Diamond Distribution due to both companies’ sales of imitation Crocs shoes. The company obtained $6 million and $55,000 in damages, respectively, against the companies.

Daniel Hart, Executive Vice President and Chief Legal & Risk Officer at CROX, said, “This judgment not only reinforces the validity of our patent rights, it also reinforces our unrelenting determination to take forceful steps to protect our brand equity.”

CROX gained 47.2% in July. However, the stock is down 40.1% year-to-date to close its last trading session at $76.80. It has gained 1.6% intraday.

Here are the factors that could affect CROX’s performance in the near term:

Mixed Financials

For the fiscal second quarter ended June 30, CROX’s revenues increased 50.5% year-over-year to $964.58 million. However, its net income and net income per common share came in at $160.32 million and $2.58, down 49.7% and 47.7% from the same period a year ago.

Mixed Valuations

In terms of its forward non-GAAP P/E, CROX is trading at 7.59x, 43.2% lower than the industry average of 13.35x. The stock’s forward non-GAAP PEG multiple of 0.36 is 68.7% lower than the industry average of 1.15.

However, in terms of its forward EV/Sales, it is trading at 2.19x, 82.4% higher than the industry average of 1.20x. Its forward Price/Book multiple of 5.19 is 90.8% higher than the industry average of 2.72.

Wall Street Expects Modest Upside

Two of the eight Wall Street analysts rating the stock have rated it Hold. The 12-month median price target of $84.38 indicates a 9.9% potential upside. The price targets range from a low of $54.00 to a high of $116.00.

POWR Ratings Don’t Indicate Enough Upside

CROX has an overall rating of C, which equates to Neutral in our proprietary POWR Ratings system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.

CROX has a Growth and Value grade of C in sync with its mixed financials and valuations. The stock also has a C grade for Momentum, consistent with the stock trading above its 50-day Moving Average of $58.81 but below its 200-Day Moving Average of $94.75.

In the 67-stock Fashion & Luxury industry, it is ranked #53.

Click here to see the additional POWR Ratings for CROX (Stability, Sentiment, and Quality).

View all the top stocks in the Fashion & Luxury industry here.

Bottom Line

The stock has been soaring in price lately. However, capital market company Victory Capital Management Inc. shed 86% of its position in CROX in the first quarter. Several other hedge funds have also reduced their positions in the company.

Moreover, given its mixed financials and valuations, it might be wise to wait for a better entry point in the stock.

How Does Crocs, Inc. (CROX) Stack Up Against its Peers?

While CROX has an overall POWR Rating of C, one might consider looking at its industry peers, J.Jill, Inc. (JILL) and Hugo Boss AG (BOSSY), which have an overall A (Strong Buy) rating, and Chico’s FAS, Inc. (CHS) and H & M Hennes & Mauritz AB (publ) (HNNMY), which have an overall B (Buy) rating.


CROX shares were trading at $76.45 per share on Friday morning, down $0.35 (-0.46%). Year-to-date, CROX has declined -40.38%, versus a -10.56% rise in the benchmark S&P 500 index during the same period.


About the Author: Anushka Dutta


Anushka is an analyst whose interest in understanding the impact of broader economic changes on financial markets motivated her to pursue a career in investment research. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
CROXGet RatingGet RatingGet Rating
JILLGet RatingGet RatingGet Rating
BOSSYGet RatingGet RatingGet Rating
CHSGet RatingGet RatingGet Rating
HNNMYGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

2 Best Stocks of All Time!

This bear market has me thinking back to my 2 best trades of all time. That being when I bought Amazon (AMZN) and Booking (BKNG) back in 2001 as they were tumbling down in the midst of a bear market...but now enjoying truly phenomenal gains. Let’s discuss what those investments had in common and how that will help us find more big winners in the years ahead. Read on below for more...

:  |  News, Ratings, and Charts

Bears Back in Charge...What Happens Next?

A month ago the bulls were claiming victory as they created a charge back over 4,000 for the S&P 500 (SPY). Since then that false narrative has been peeled away and investors are more honestly looking at the bleak outlook formed by high inflation and a hawkish Fed. That explains why we are back retesting the June lows. Now we have to ponder what comes next and how to trade our way to profits. Read on below for the full story...

:  |  News, Ratings, and Charts

3 Healthcare Stocks Under $100 to Buy Right Now

The rising prevalence of chronic diseases and the aging population are major growth drivers for the healthcare industry. In addition, increased investments in technological advancements should further bolster the industry’s growth. Thus, we think it may be prudent to buy quality healthcare stocks Pfizer Inc. (PFE), Merck & Co. (MRK), and Bristol-Myers Squibb (BMY), which are currently trading under $100. Read on…

:  |  News, Ratings, and Charts

Cut These 2 Stocks From Your Portfolio Right Now

The Fed succeeding in a ‘soft landing’ seems unlikely. Analysts are expecting a recession soon. So, with the rising odds of the Fed raising rates aggressively, it could be wise to steer clear of fundamentally weak stocks Roblox (RBLX) and Affirm Holdings (AFRM). Read on…

:  |  News, Ratings, and Charts

3 Healthcare Stocks Under $100 to Buy Right Now

The rising prevalence of chronic diseases and the aging population are major growth drivers for the healthcare industry. In addition, increased investments in technological advancements should further bolster the industry’s growth. Thus, we think it may be prudent to buy quality healthcare stocks Pfizer Inc. (PFE), Merck & Co. (MRK), and Bristol-Myers Squibb (BMY), which are currently trading under $100. Read on…

Read More Stories

More Crocs, Inc. (CROX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CROX News